التداخل بين التبغ والتدخين وتوفاسيتينيب

Patients who are current or past smokers are at additional increased risk.

Patients who are current or past smokers are at additional increased risk [see Clinical Studies (14.6) ].

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with XELJANZ/XELJANZ XR, particularly in patients with a known malignancy (other than a successfully treated NMSC), patients who develop a malignancy while on treatment, and patients who are current or past smokers.

The incidence rate of lung cancers per 100 patient-years among current and past smokers was 0.59 for XELJANZ tablets 10 mg twice a day, 0.48 for XELJANZ tablets 5 mg twice a day, and 0.27 for TNF blockers [see Clinical Studies (14.6) ] .